OBJECTIVES: Uncoupling protein 2 (UCP2) is a recently described homologue of the uncoupling protein of brown adipocytes (UCP1), which is expressed at high levels in human white adipose tissue. Studies were undertaken (1) to establish whether the expression of UCP2 mRNA varies in a depot-related manner in isolated human adipocytes, (2) to determine whether thiazolidinedione exposure in¯uences the expression of UCP2 mRNA in cultured human preadipocytes, and (3) to determine whether human UCP2 is targeted to mitochondria when transfected into mammalian cells. SUBJECTS: Abdominal subcutaneous and omental adipose tissue biopsies were obtained from adult patients undergoing elective intra-abdominal surgical procedures. MEASUREMENTS: A competitive reverse transcriptase-polymerase chain reaction (RT-PCR) was used to quantify UCP2 mRNA expression in human omental and subcutaneous adipocytes, and in cultured human preadipocytes differentiated in vitro using the thiazolidinedione, BRL49653. Chinese hamster ovary cells were transfected with a vector expressing human UCP2, and its cellular localization was determined by confocal immuno¯uorescence microscopy. RESULTS: Adipocytes isolated from human omentum consistently expressed more UCP2 mRNA than did subcutaneous adipocytes from the same subjects (mean fold difference 2.92 AE 0.44 P`0.001, n 11) with no effect of gender or body mass index being seen. BRL49653 treatment of subcutaneously, but not omentally, derived preadipocytes stimulated expression of UCP2 mRNA (5.1 AE 1.1 fold). Transfected human UCP2 was detected exclusively in mitochondria of CHO cells. CONCLUSIONS: Increased expression of UCP2 in human omental adipose tissue relative to subcutaneous adipose tissue is related to the expression levels in adipocytes per se, a ®nding which may relate to the particular functional attributes of this sub-population of adipocytes. Furthermore, BRL 49653 has site-speci®c effects of on the expression of UCP2 in human preadipocytes, a ®nding which may be relevant to the therapeutic effects of such compounds. Finally we present evidence for the mitochondrial localisation of human UCP2.
Introduction
The recent identi®cation of two mammalian homologues of the brown adipose tissue uncoupling protein (UCP1), uncoupling proteins 2 and 3 (UCP2 and UCP3), has greatly stimulated research into the molecular mechanisms of energy expenditure, 1 ± 3 particularly as the UCP2a3 locus on human chromosome 11 has been genetically linked to obesity, hyperinsulinaemia and resting energy expenditure (REE). 1, 4, 5 In primary amino acid sequence both UCP2 and UCP3 are highly homologous to UCP1 (59% and 57%), and both reduce electrical potential across the mitochondria of yeast cells overexpressing these proteins. 1, 6 However, a speci®c uncoupling function for these proteins in mammalian cells has not yet been con®rmed. Furthermore, their localization to the mitochondria of mammalian cells has not been de®nitively demonstrated.
In various studies UCP2 mRNA expression in rodent and human adipose tissue has been found to increase under conditions of high free-fatty acid (FFA)¯ux, such as fasting 7 and high fat-feeding. 1, 8, 9 Given the known higher intrinsic lipolytic activity and the more rapid triglyceride turnover in human omental compared to subcutaneous adipose depots, 10 ± 12 it is notable that Oberko¯er et al have recently reported higher expression of UCP2 mRNA in omental, compared to subcutaneous, adipose depots. 13 In addition, this study reported lower levels of omental UCP2 mRNA expression in obese vs lean subjects, implicating UCP2 in the pathophysiology of obesity. How-ever, as UCP2 is expressed in a number of cell types, including macrophages, 1 it is not clear whether the site-speci®c expression reported in this study is related to a regional difference in UCP2 expression in adipocytes or in other cellular constituents of omental adipose tissue, eg immune cells.
Thiazolidinediones are a novel class of insulin sensitizing agents which have been shown to reduce hyperglycaemia, hyperinsulinaemia and hypertriglyceridaemia in type 2 diabetes mellitus. 14 These effects appear to be mediated by the nuclear receptor peroxisome proliferator activated receptor gamma (PPAR g). 15 In human and murine cell culture systems activation of PPARg promotes adipogenesis 16, 17 and, as obesity is strongly associated with type 2 diabetes mellitus, the therapeutic ef®cacy of thiazolidinediones might be considered somewhat paradoxical.
However, if these agents also stimulated energy expenditure this might contribute to the resolution of this apparent paradox. In this regard, ciglitazone, an early member of this drug family, was reported to increase energy expenditure in rodents, 18 and we have recently demonstrated that BRL49653 stimulated UCP1 expression in preadipoctyes from a variety of human adipose tissue depots. 19 Darglitazone, a potent thiazolidinedione, has been shown to stimulate UCP2 expression in 3T3-L1 preadipocytes, 20 while pioglitazone increased levels of UCP3 mRNA in a dose dependent manner in cultured rat adipocytes, though no signi®cant change in UCP2 mRNA was reported. 21 In this study we have addressed a number of these issues in relation to human UCP2: (1) we have quanti®ed UCP2 mRNA expression in human adipocytes isolated from omental and subcutaneous sites; (2) we have examined the effects of BRL49653 on UCP2 expression in omental and subcutaneous human preadipocytes; and (3) we have developed an antibody to human UCP2 and used this to establish the cellular localisation of UCP2 in transfected cells by confocal immuno¯uorescence microscopy.
Methods

Subjects
Abdominal subcutaneous and omental adipose tissue biopsies were obtained from adult patients undergoing elective surgery. All patients were fasted for at least 6 h pre-operatively, and all underwent general anaesthesia. None of the patients had diabetes or severe systemic illness. For analysis of mRNA levels in omental and subcutaneous adipocytes the study group consisted of six females and ®ve males aged (meanAE s.e.m.) 53. 
Adipocyte isolation and Preadipocyte cell culture
Isolated adipocytes were prepared by a method modi®ed from that of Rodbell. 22 Adipose tissue biopsies were chopped ®nely with scissors and adipocytes isolated by collagenase digestion (Hanks Balanced Salt Solution (HBSS) containing 3 mgaml collagenase (type II) and 1.5% bovine serum albumin) in a shaking water bath at 37 C for up to 60 min. Mature adipocytes were separated from the stromal-vascular cells through an inert oil, bis(3,5,5 trimethylhexyl) phthalate (Fluka Chemicals, Gillingham, UK). After elimination of red blood cells using an erythrocyte lysis buffer, the stromal-vascular cells were cultured in Dulbeccos modi®ed Eagles medium (DMEMaHams F-12 medium supplemented with 10% fetal bovine serum, antibiotics and L-glutamine (2 mM)). Cultures were passaged a maximum of three times and grown to con¯uence. At con¯uence, the medium was substituted with a serum-free medium supplemented with additions as described, 16, 23 and the TZD, BRL 49653 (10 77 M) or vehicle (DMSO). The preadipocytes were cultured for 10 or 15 days in the presence of BRL 49653 or vehicle. Differentiation was assessed by assay of G3PDH as previously described. 16 The results show the mean value of G3PDH activity from individual samples measured in three wells AE BRL 49653 and are expressed as mU of G3PDH activitya mg protein; 1 mU was equal to the amount catalysing the oxidation of 1 nmol of NADH min 71 .
Measurement of UCP2 mRNA by quantitative RT-PCR
Messenger RNA was quantitated using a wellvalidated method utilizing a speci®c mutant mRNA standard for each reaction which we have described previously. 24 ± 26 Total RNA was extracted from mature adipocytes and cultured preadipocytes by the guanidium thiocyanate-phenol method (TRIzolReagent, Sigma, St Louis, MO). The integrity of the RNA was checked on a 2% agarose gel and RNA concentration was measured by spectrophotometry. UCP-2 mRNA was measured quantitatively using a synthesized mutant standard RNA which resembled the wild-type RNA apart from a single base change, which introduced a Hind III restriction endonuclease site. The mutant was constructed by reverse transcribing human adipocyte RNA using random hexamers as primers. The cDNA was then ampli®ed by PCR using the following sense primer which introduces a T7 polymerase promoter sequence at the 5 H end of the UCP-2 sequence and a base change which inserts a Hind III recognition site, T for C at position 320 (underlined): 5
H -taatacgactcactatagggcgaccatggtgcgtactgagggcccccgaagcttctacaatgggctgg, and the following antisense primer sequence: 5 H -gacaatggcattacgagcaac. T7 polymerase was then used to synthesize C for 5 min (1 cycle). For each subject RNA a reaction in which the reverse transcriptase and the mutant standard were omitted acted as a control for any residual DNA in the subject of interest. The ampli®ed products were digested with Hind III and then fractionated on a 2% agarose gel stained with ethidium bromide. The densities of the wild-type and mutant standard bands were measured using the National Institutes of Health Image software and the point at which they were equal (x 0) was determined. To ascertain the relative abundance of UCP2 the equivalence points were compared between samples of RNA from omental and subcutaneous adipocytes and from preadipocytes treated with BRL 49653. To con®rm that the PCR product was UCP2, direct sequencing of the PCR product was performed using the sense and antisense primers for each respective strand. All PCR conditions were checked extensively during optimization and validation, and heteroduplex formation was not a feature. The results of quantitative RT-PCR are presented as mean AE s.e.m. of duplicate measurements.
Western blotting and confocal immuno¯uorescence microscopy
Western blotting. Human UCP2 cDNA (a gift from Dr Martin Brand, Cambridge University) was inserted into the expression vector pRc.CMV (Invitrogen) using Hind IIIaXba I. Cultured Chinese hamster ovary (CHO) cells were then either mock transfected or transfected with this expression vector using Lipofectamine (Gibco BRL, Paisley, UK), according to the manufacturers protocol. After 24 h transfected and mock transfected cells were washed in ice-cold PBS and lysed with a lysis buffer as described previously. 27 Lysates containing 20 mg were resolved by 12% SDS ± PAGE and proteins transferred to Immobilon-P membrane. Membranes were blocked with PBS containing 2% BSA for 1 h at room temperature, followed by overnight incubation with primary antibody, rabbit anti-UCP2 (generated against amino acids 1 ± 10 of human UCP2 N-terminus) dilution 1:1000. Alternatively, rabbit anti-UCP2 (Calbiochem-Novabiochem UK Ltd, Nottingham, UK) dilution 1:1000 was used as primary antibody. After washing with PBS, membranes were incubated with secondary antibody, horseradish peroxidase linked goat anti-rabbit (DAKO AaS, Denmark) dilution 1:10,000, at room temperature for 30 min. After a further washing step with PBS, membranes were treated with enhanced chemiluminescent reagent (ECL, Amersham International plc, Buckinghamshire, UK) and chemiluminescence was detected by exposure to X-ray ®lm.
Confocal immuno¯uorescence microscopy. CHO cells were cultured on coverslips and then transfected with either pRc.CMV containing human UCP2 cDNA (as described above) or empty vector (mock-transfected) using Tfx 10 reagent (Promega, Southampton, UK). After 24 h, MitoTracker Red CMXRos (Molecular Probes Europe BV, Leiden, The Netherlands) was added to the culture medium (®nal concentration 50 nM) and incubated at 37 C for 1 h. After washing with PBS cells were ®xed using 2% paraformaldehyde in PBS for 2 min at room temperature. After a further wash with PBS, cells were permeabilized using 0.1% Triton-100 in PBS again for 2 min at room temperature. The coverslips were incubated ®rst with primary antibody, rabbit anti-UCP2 (generated against amino acids 1 ± 10 of human UCP2 N-terminus) dilution 1:50, for 2 h at room temperature and then secondary conjugate,¯uorescein isothiocyanate (FITC) goat anti-rabbit IgG (Sigma, Poole, UK) dilution 1:50, for 1 h at room temperature in the dark. UCP2 protein and the mitochondrial marker MitoTracker were detected by confocal microscopy performed using a Bio-Rad MRC 1000 apparatus (Bio-Rad Laboratories Inc., Hertfordshire, UK). Controls for non-speci®c binding included pre-immune serum and secondary conjugate alone. UCP2 protein expression in transfected CHO cells was also detected by confocal immuno¯uorescence microscopy using a commercially available primary antibody, rabbit anti-UCP2 (Calbiochem-Novabiochem, Nottingham, UK) and the FITC conjugate.
Statistical analysis
Data are presented as mean AE s.e.m. Statistical differences were determined using Student's t-test for paired or unpaired data, as appropriate.
Results
UCP2 mRNA expression in human adipocytes and preadipocytes
Adipocytes. UCP2 mRNA expression was measured in isolated mature human adipocytes from subcutaneous and omental adipose depots by quantitative RT-PCR (Figure 1) . In all 11 subjects studied, the level of UCP2 mRNA expression was greater in omental compared to subcutaneous adipocytes ( Table 1 ). The
Human uncoupling protein 2 expression JE Digby et al mean ratio ( AE s.e.m.) of omental to subcutaneous adipocyte UCP2 mRNA expression was 2.92AE 0.44 (P`0.001, n 11), with no sexual dimorphism being apparent (males, 2.88 AE 0.33 (n 5), and females, 2.95AE 0.74 (n 6)). No signi®cant correlation was found between BMI and UCP2 mRNA expression in omental or subcutaneous adipocytes (data not shown).
Cultured preadipocytes. UCP2 mRNA expression was detectable in primary cultures of human preadipocytes. In contrast with mature adipocytes, UCP2 mRNA levels were similar in omental and subcutaneous preadipocytes not treated with BRL 49653 (Figure 2a) . Treatment with BRL49653 for 10 days resulted in a 5.1 AE 1.1-fold increase (meanAE s.e.m., P`0.025, n 5) in UCP2 expression levels in subcutaneous preadipocytes compared with those of the vehicle-treated cells (Figure 2a) . No signi®cant increase in UCP2 mRNA was observed in omental preadipocytes (n 3) treated with BRL49653 ( Figure  2a) . The increase in UCP2 mRNA expression observed in subcutaneous preadipocytes treated with BRL49653 was associated with preadipocyte differ- Figure 1 Representative results of a quantitative RT-PCR showing a 3-fold greater expression of UCP2 mRNA in omental (Om) compared to subcutaneous (Sc) adipocytes. Following RT-PCR, products were digested with Hind III and analysed by 2% agarose gel electrophoresis stained with ethidium bromide (upper panel). Omental (Om) tracks 1 ± 8 and subcutaneous (Sc) tracks 1 ± 8 show serial 1:2 dilutions of the mutant UCP2 (Mt) RNA standard (lower bands), 1:1000, 1:2000, 1:4000, 1:8000, 1:16,000, 1:32,000, 1:64,000 and 1:128,000. The upper band is wild-type UCP2 (Wt) ampli®ed cDNA. The graphs below show the calibration curves plotted from the results of the densitometry measurements. Both curves are rectilinear giving a slope near to 1, which demonstrates that the mutant (Mt) and wild-type (Wt) RNAs were ampli®ed with equal ef®ciency. The mutant concentration at which the band intensities were calculated to be equal were 10
74.106 for omental and 10 74.174 for subcutaneous adipocytes giving approximately 3-fold more UCP2 mRNA in omental adipocyte RNA than in subcutaneous RNA from the same individual. Table 1 The expression of UCP2 is greater in omental compared to that measured in subcutaneous adipocytes. The table shows the ratio of omental (Om) to subcutaneous (Sc) UCP-2 mRNA levels in isolated adipocytes from 11 subjects (UCP2 mRNA levels expressed as arbitrary units). In all cases studied, the expression of UCP2 was higher in omental compared to that measured in subcutaneous adipocytes from the same individual. In female patients (n 6) the difference was 2.95 AE 0.74-fold (mean AE s.e.m.) omental vs subcutaneous (P`0.001) and in male patients (n 5) the difference was 2.9 AE 0. 33 Human uncoupling protein 2 expression JE Digby et al entiation as measured by a 34 AE 9.1-fold (mean AE s.e.m.) increase in G3PDH activity above that seen in vehicle-treated cells (Figure 2b ). In contrast, omental preadipocytes showed only a small (4.8AE 1.0, n 3) fold increase in G3PDH activity in response to BRL49653, consistent with our previous report of the refractoriness of human omental preadipocytes to differentiation by thiazolidinediones 7 (Figure 2b ).
Cellular localization of UCP2 in transfected CHO cells
To validate the anti-UCP2 antibodies used in determining the cellular localization of human UCP2, protein lysates from CHO cells transfected with an expression vector encoding human UCP2 cDNA were analysed by immunoblotting. In CHO cells overexpressing the protein a speci®c band was detected at the appropriate size for human UCP2 (32 kDa) using a rabbit anti-UCP2 generated against amino acids 1 ± 10 of human UCP2 N-terminus. Signi®cantly, this was absent in mock transfected CHO cells (Figure 3a) . In addition, a band of appropriate size for human UCP2 was also detected in transfected CHO cells with another rabbit anti-UCP2 (Calbiochem-Novabiochem, Nottingham, UK), and again this band was not detected in mock transfected cells (Figure 3b ). Identical non-speci®c band patterns were observed in both transfected and mock transfected cell lysates with both primary antibodies. To determine whether human UCP2 was localized to mitochondria, transfected CHO cells were analysed by confocal immuno¯uorescent microscopy for colocalization of UCP2 immunoreactivity and a speci®c uorescent mitochondrial marker MitoTracker. UCP2 immunoreactivity co-localized completely with MitoTracker (Figure 4a ± c) , and no UCP2 staining was seen outside the mitochondria. This ®nding was con®rmed in independent experiments with the two different anti-UCP2 antibodies. Of note, co-localization of UCP2 immunoreactivity and Mitotracker was not detected in mock transfected CHO cells ( Figure  4d , e), indicating that non-speci®c primary antibody binding did not contribute signi®cantly to the confocal immuno¯uorescence signal observed in transfected cells. Furthermore, speci®c immunostaining was not observed in controls for non-speci®c binding, which included pre-immune serum and secondary conjugate only control samples (data not shown).
Discussion
The recently identi®ed proteins UCP2 and UCP3 share many of the characteristics of mitochondrial carrier proteins including six predicted transmembrane domains, three energy transfer protein motifs and a C-terminal nucleotide binding domain.
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When over-expressed in yeast they lower mitochondrial membrane potential, which suggests a role for these proteins in uncoupling of respiration and nonshivering thermogenesis, 1,3 although studies have not de®nitively demonstrated that UCP2a3 are selective mitochondrial uncouplers. To our knowledge, speci®c localization of these proteins to mitochondria in mammalian cells has itself not been reported. One of the main reasons for this has been the dif®culty in obtaining primary antibodies speci®c for UCP2. We describe two antibodies which appear to detect human UCP2 by Western blotting and confocal immuno¯uorescence microscopy when human UCP2 is overexpressed in transiently transfected CHO cells. Previously Qian et al 28 used immunocytochemical analysis to demonstrate UCP2 expression in rodent adipocytes, but did not use a co-localizing marker to con®rm the mitochondrial location. Using confocal microscopy and immuno¯uorescence our results show that human UCP2, expressed in transfected CHO cells, co-localizes exclusively with a speci®c mitochondrial marker. While this ®nding does not con®rm that human UCP2 acts as an uncoupling protein, it does establish a basic requirement necessary for such a function. Even though these antibodies have been used successfully to identify UCP2 when overexpressed in CHO cells, we have not been successful in using them to directly examine UCP2 protein expression in human adipose tissue. This may be due, in part, to limited sensitivity of these antibodies. In addition, the in-house antibody appears to cross-react with a protein of similar molecular weight to UCP2 (approximately 30 kDa) in human adipose tissue lysates, a feature not noted with the commercially available antibody (data not shown).
The UCP2 locus has been linked to obesity, hyperinsulinaemia and resting energy expenditure 1,4,5 suggesting that variation in expression of UCP2 could in¯uence the development of obesity and its associated metabolic sequelae, eg atherosclerosis, dyslipidaemia and hypertension. As a result of the stronger association of visceral, rather than generalized, adiposity with these adverse metabolic consequences, 29 ± 32 Figure 3 Western blot detection of UCP2 in transfected CHO cells. CHO cells were transfected with either pRc.CMV-hUCP2 or empty vector (mock-transfected), as indicated. Cell lysates were prepared and Western blot analysis performed using (a) rabbit anti-UCP2 (generated against amino acids 1 ± 10 of human UCP2 N-terminus) and (b) rabbit anti-UCP2 (Calbiochem-Novabiochem, Nottingham, UK). A 32 kDa band corresponding to expected molecular weight of human UCP2 is seen in transfected ( ), but is absent in mock-transfected (7) protein lysates.
Human uncoupling protein 2 expression JE Digby et al there has been considerable interest in the exploration of regional differences in adipocyte function and gene expression in man. 25, 33 In this regard, Oberko¯er et al recently reported that UCP2 was more highly expressed in omental than in subcutaneous adipose tissue, and there was altered expression of UCP2 in omental adipose tissue between lean and obese subjects, implicating UCP2 in the pathophysiology of obesity. 13 We have re®ned these observations relating to adipose tissue depot-speci®c UCP2 expression by examining its expression in isolated human adipocytes, and con®rm that there is enhanced UCP2 expression in omentally, relative to subcutaneously, derived cells. Indeed the mean 2.9-fold omental:sub- Human uncoupling protein 2 expression JE Digby et al cutaneous UCP2 mRNA ratio found in this study is greater than that reported by Oberko¯er et al. Notably, of the 10 adipocyte genes studied to date in our laboratory, 24, 25 UCP2 has the highest omental:subcutaneous ratio of expression. These observations raise questions about the relationship between intrinsic metabolic properties of omental adipocytes and the control of UCP2 expression. Several workers have examined changes in UCP2 expression in response to physiological manipulations in rodents and humans. Millet et al reported increased UCP2 mRNA expression in human adipose tissue in response to prolonged fasting. 7 Interestingly, however, chronic high fat feeding also led to upregulation of UCP2 mRNA expression in rodents. 1, 8, 9 If UCP2 was primarily concerned with the control of energy expenditure alone, these ®ndings would appear to be contradictory. However, both states are characterized by increased FFA¯ux within the adipocyte and it has been suggested that UCP2 mRNA expression may be better correlated with fatty acid metabolism than with metabolic ef®-ciency. 34 Omental adipose tissue is known to have a higher rate of lipid turnover than subcutaneous adipose tissue, and this is related to a greater sensitivity to the lipolytic effects of catecholamines 35 and less sensitivity to the anti-lipolytic effects of insulin. 36, 37 Thus, the greater UCP2 expression in human omental versus subcutaneous adipocytes would be consistent with a relationship between FFA¯ux and UCP2 expression.
If the uncoupling proteins are involved in energy dissipation in man, their stimulation by thiazolidinediones might be of relevance to the ultimate therapeutic ef®cacy of these compounds. Camirand et al 20 have recently reported that the thiazolidinedione darglitazone signi®cantly increased UCP2 mRNA expression in murine preadipocyte and adipocyte cell lines. We have previously reported a stimulatory effect of BRL49653 on UCP1 expression in human pre-adipocytes from all depots studied, even when the cells did not respond to the prodifferentiative effects of these agents. 19 Here we now report that UCP2 expression in preadipocytes is stimulated by BRL49653, but only in the subcutaneous depot, where these compounds robustly promote adipocyte differentiation. 16 In the case of omentally-derived preadipocytes, where little adipocyte differentiation occurs in response to thiazolidinediones as shown by G3PDH activity, there was no signi®cant enhancement of UCP2 expression. This suggests that the TZD induced increase in UCP2 mRNA expression in subcutaneous preadipocytes may be related to a generalized enhancement of cellular differentiation, although a direct upregulation of UCP2 gene expression may also be a contributory factor. In addition, these ®ndings point toward the existence of fundamental differences in the transcriptional regulation of UCP1 and 2 in response to the activation of the nuclear hormone receptor PPARg in preadipocytes.
Conclusions
The ®nding that human UCP2 is targeted exclusively to the mitochondria of transfected cells is not unexpected, but nonetheless provides important con®rma-tion of the assumed cellular localization of this protein. The demonstration that UCP2 mRNA expression is consistently and signi®cantly greater in human omental than in subcutaneous adipocytes may relate to the higher lipid turnover in this adipose tissue depot and adds to the growing body of suggestive evidence linking UCP2 and FFA¯ux. Finally, the fact that the thiazolidinedione BRL49653 markedly increases UCP2 mRNA expression in subcutaneously-derived human preadipocytes provides a further potential mechanism contributing to the bene®cial metabolic effects of these compounds in humans.
